I-Viibryd vs. Lexapro: Umehluko, ukufana, nokuthi yikuphi okungcono kuwe
Izidakamizwa Vs. UmnganiUkubuka konke kwezidakamizwa nokwehluka okuyinhloko | Izimo zilashwa | Ukusebenza | Ukutholakala komshuwalense nokuqhathaniswa kwezindleko | Okuqhamuka uma udla imishanguzo | Ukusebenzisana kwezidakamizwa | Izexwayiso | Imibuzo evame ukubuzwa
IViibryd (vilazodone) neLexapro (escitalopram) yimithi kadokotela esetshenziselwa ukwelapha ukucindezeleka okukhulu (MDD). Zombili lezi zidakamizwa zingasiza ekwelapheni izimpawu zokucindezeleka, ezingafaka imizwa yokudabuka isikhathi eside, ukuphelelwa amandla, nezinguquko zokulala. I-Viibryd noma i-Lexapro ingahle inqunywe ngemuva kokuhlolwa kwezokwelapha ngumhlinzeki wezokunakekelwa kwezempilo ogxile kwezengqondo.
Kokubili iViibryd neLexapro yizidambisi zokucindezela ezisebenza ikakhulu ukwandisa umsebenzi we-serotonin ebuchosheni. I-Serotonin iyi-neurotransmitter yamakhemikhali okukholelwa ukuthi ibamba iqhaza elibalulekile emizweni nasezizweni zenhlalakahle. IViibryd neLexapro basebenza njenge-serotonin reuptake inhibitors (SSRIs), esiza ukwandisa amazinga e-serotonin jikelele ebuchosheni.
Yize yomibili imishanguzo ingasetshenziswa ukwelapha ukucindezeleka, inomehluko othile wokuthi zisetshenziswa kanjani nokuthi zisebenza kanjani.
Uyini umehluko omkhulu phakathi kweViibryd neLexapro?
I-Viibryd
IViibryd yigama lomkhiqizo le-vilazodone. Ekuqaleni kwavunywa yi-Food and Drug Administration (i-FDA) ngo-2011 ukwelapha ukucindezeleka okukhulu. Okwamanje ayikho inguqulo ejwayelekile etholakalayo emakethe. Ngaphezu kokuhlukaniswa njenge-SSRI, iViibryd futhi iyingxenye ye-5-HT1A receptor agonist.
I-Viibryd iza njenge-10 mg, 20 mg, kanye ne-40 mg tablet yomlomo ethathwa kanye nsuku zonke ngokudla. IViibryd kungenzeka ingasebenzi kahle uma ingathathwa nokudla. Ifinyelela emazingeni aphezulu egazini ngemuva kwamahora amahlanu futhi inempilo yesigamu cishe amahora angama-25 .
I-Lexapro
ILexapro yigama lomkhiqizo le-escitalopram. Kwakuyi-FDA evunyelwe ngo-2002 ukuphatha i-MDD kubantu abadala nasebasha abaneminyaka engu-12 kuya kwengu-17 ubudala. Ngaphezu kokucindezeleka, iLexapro ingaphatha ukukhathazeka okuvamile. Izinhlobo ezijwayelekile zeLexapro ziyatholakala futhi emakethe.
I-Lexapro ingathathwa njengethebhulethi yomlomo ngamandla we-5 mg, 10 mg, noma ama-20 mg. Imvamisa kuthathwa kanye ngosuku noma ngaphandle kokudla. ILexapro ifinyelela amazinga aphakeme egazi kungakapheli amahora amahlanu futhi inempilo yesigamu kufika emahoreni angama-32 .
| Umehluko omkhulu phakathi kweViibryd neLexapro | ||
|---|---|---|
| I-Viibryd | I-Lexapro | |
| Isigaba sezidakamizwa | I-Serotonin Reuptake Inhibitor ekhethiwe (SSRI) I-agonist eyingxenye ye-5-HT1A | I-Serotonin Reuptake Inhibitor ekhethiwe (SSRI) |
| Isimo somkhiqizo / ejwayelekile | Ayikho inguqulo ejwayelekile etholakalayo | Uhlobo lomkhiqizo nohlobo olujwayelekile luyatholakala |
| Ngubani igama elijwayelekile? | Vilazodone | I-Escitalopram |
| Izidakamizwa zingena ngaziphi izinhlobo? | Ithebhulethi yomlomo | Ithebhulethi yomlomo |
| Uyini umthamo ojwayelekile? | 20 mg kanye ngosuku | 20 mg kanye ngosuku |
| Yelashwa isikhathi esingakanani? | Isikhati eside | Isikhati eside |
| Ubani ovame ukusebenzisa umuthi? | Abantu abadala | Abantu abadala nentsha |
Izimo eziphathwe yiViibryd neLexapro
I-Viibryd neLexapro yizidambisi ezigunyazwe yi-FDA ezisetshenziselwa ukwelapha ukukhathazeka okukhulu. Noma imuphi umuthi ungabhalwa ngokuhlanganiswa ne-psychotherapy kanye nezinguquko zendlela yokuphila ukusiza ukunciphisa izimpawu zokucindezeleka.
ILexapro nayo i-FDA ivunyelwe ukwelapha ukukhathazeka ngokweqile (GAD). Yize kungavunyelwe ukukhathazeka, i-Viibryd sekufundwe ekuhlolweni kwemitholampilo ekwelapheni ukukhathazeka. I-Viibryd noma i-Lexapro kwesinye isikhathi ingasetshenziswa ngaphandle kwelebuli ukwelapha ukuphazamiseka okuphoqelela ngokweqile (OCD).
| Isimo | I-Viibryd | I-Lexapro |
| Ukucindezeleka okukhulu | Yebo | Yebo |
| Isifo sokukhathazeka esijwayelekile | Ngaphandle kwelebula | Yebo |
| Ukuphazamiseka okubangelwa ukucindezela | Ngaphandle kwelebula | Ngaphandle kwelebula |
Ngabe iViibryd noma iLexapro isebenza kangcono?
Kokulingwa okukodwa okungahleliwe, i-vilazodone ne-escitalopram zaqhathaniswa ikhanda-ekhanda phakathi kwesampula seziguli ezingama-50. Isikali se-Hamilton Anxiety Scale (HAM – A) ne-Hamilton Depression Rating Scale (HAM-D) sehlisiwe kuwo womabili amaqembu okwelashwa. Kodwa-ke, i-escitalopram itholakele ukwehlisa inani eliphelele le-HAM-A ne-HAM-D ngaphezu kwe-vilazodone (P<0.0001).
Ekubuyekezweni okuhlelekile, i-escitalopram yayikhona uma kuqhathaniswa nezinye izidambisi gciwane eziyisithupha , kufaka phakathi i-fluoxetine, i-citalopram, ne-sertraline. Lolu cwaningo lubuyekeze ukuhlaziywa okuningi kwe-meta futhi lwathola ukuthi i-escitalopram yayisebenza ngempumelelo futhi yehlisa izimpawu zokucindezeleka ngokushesha kunamanye ama-SSRI.
Uma kuqhathaniswa ne-placebo, noma akukho ukwelashwa, i-Viibryd neLexapro yizinketho ezisebenzayo zokwelapha ukucindezeleka. Noma kunjalo, umehluko endleleni umuntu aphendula ngayo ingadlala indima ebalulekile ekutheni i-antidepressant ingasebenza kanjani. Ngakho-ke, kubalulekile ukubonisana nomhlinzeki wezokunakekelwa kwempilo ngezeluleko zezokwelapha lapho uqala noma ukushintshela ku-antidepressant entsha .
Ukuhlanganiswa kanye nokuqhathaniswa kwezindleko kweViibryd vs. Lexapro
IViibryd itholakala kuphela njengomuthi wegama lomkhiqizo. Ngalesi sizathu, kungaba inketho ebiza kakhulu uma iqhathaniswa namanye ama-anti-depressants. Amanye ama-Medicare nezinhlelo zomshuwalense zingahlanganisa iViibryd. Intengo emaphakathi yemali yeViibryd icishe ibe ngu- $ 389. Ukusebenzisa isigqebhezana se-SingleCare Viibryd kungehlisa izindleko kuye ku- $ 278 kuma-pharmacy abambe iqhaza.
ILexapro iyatholakala njengegama lomkhiqizo nemithi ejwayelekile. Uma kuqhathaniswa ne-Viibryd, kuyindlela eshibhile. Iphinde imbozwe iningi le-Medicare nezinhlelo zomshuwalense. Intengo yemali ejwayelekile yeLexapro ejwayelekile icishe ibe $ 177. Ngesigqebhezana sesaphulelo esivela kwaSingleCare, ungathola okujwayelekile cishe u- $ 15.
| I-Viibryd | I-Lexapro | |
| Ngokuvamile embozwe umshwalense? | Yebo | Yebo |
| Imbozwe ngokwejwayelekile yi-Medicare Part D? | Yebo | Yebo |
| Ubuningi | 20 mg kanye ngosuku (inani lamaphilisi angama-30) | 20 mg kanye ngosuku (inani lamaphilisi angama-30) |
| I-Medicare copay ejwayelekile | $ 1– $ 11 | $ 0– $ 30 |
| Izindleko ze-SingleCare | $ 278 + | $ 15 + |
Imiphumela emibi ejwayelekile yeViibryd vs. Lexapro
Imiphumela emibi kakhulu ye-Viibryd isifo sohudo, isicanucanu, umlomo owomile, ikhanda elibuhlungu, nokujuluka okwandayo. Eminye imiphumela emibi engaba khona ifaka phakathi isiyezi, ukozela, ukuqwasha, nobuhlungu bamalunga (arthralgia), phakathi kwabanye.
Imiphumela emibi kakhulu yeLexapro yisicanucanu, ikhanda, isifo sohudo, ukujuluka okwandayo nomlomo owomile. Eminye imiphumela emibi engaba khona yeLexapro ingafaka ukuqunjelwa kanye nezimpawu ezinjengomkhuhlane.
I-Viibryd neLexapro, njengamanye ama-anti-depressants , kungadala ushintsho ekudleni. Lokhu kungaholela ekutholeni isisindo noma ekunciphiseni kwesisindo kwabanye abantu.
Kokubili iViibryd neLexapro kungadala nemiphumela emibi kwezocansi . Ukusetshenziswa kwe-anti-depressant kungadala ukwehla kwe-sex drive (libido). IViibryd neLexapro nakho kungadala ukungasebenzi kahle kwezocansi, njengokungasebenzi kahle kwe-erectile, nezinkinga nge-ejaculation. Ngoba iViibryd nayo isebenza njenge-agonist yokwamukela engu-5-HT1A, ingahle ibe ne- ingozi ephansi yemiphumela emibi yezocansi kuneLexapro.
| I-Viibryd | I-Lexapro | |||
| Umphumela oseceleni | Kusebenza? | Imvamisa | Kusebenza? | Imvamisa |
| Uhudo | Yebo | 26% | Yebo | 8% |
| Ukuqunjelwa | Akunjalo | - | Yebo | 3% |
| Ukujuluka okwengeziwe | Yebo | * | Yebo | 5% |
| Isicanucanu | Yebo | 22% | Yebo | ishumi nanhlanu% |
| Umlomo owomile | Yebo | 8% | Yebo | 6% |
| Ukugaya ukudla | Yebo | amaphesenti amabili | Yebo | 3% |
| Izimpawu ezinjengomkhuhlane | Akunjalo | - | Yebo | 5% |
| Ubuhlungu bekhanda | Yebo | ishumi nanhlanu% | Yebo | 24% |
| Isiyezi | Yebo | 6% | Yebo | 5% |
| Ukozela | Yebo | 4% | Yebo | 6% |
| Ukuqwasha | Yebo | 7% | Yebo | 9% |
| Ukushaya kancane | Yebo | 1% | Yebo | * |
| Ukwanda kwesifiso | Yebo | 1% | Yebo | * |
| Ukuzuza kwesisindo | Yebo | 1% | Yebo | * |
| Ukwehla kwesifiso sokudla | Yebo | * | Yebo | 3% |
| Ubuhlungu obuhlangene | Yebo | amaphesenti amabili | Yebo | * |
| Ukungasebenzi kahle kwe-Erectile | Yebo | 3% | Yebo | 3% |
| Ukuphazamiseka kokuchama | Yebo | 1% | Yebo | 9% |
| Kwehlisiwe i-libido | Yebo | 4% | Yebo | 3% |
* akubikiwe
Ukuvama akususelwa kudatha evela esivivinyweni sekhanda kuya ekhanda. Lokhu kungenzeka kungabi uhlu oluphelele lwemiphumela emibi engenzeka. Sicela ubheke udokotela wakho noma umhlinzeki wezokunakekelwa kwempilo ukuze ufunde kabanzi.
Umthombo: DailyMed ( I-Viibryd ), IDailyMed ( I-Lexapro )
Ukusebenzisana kwezidakamizwa kweViibryd vs. Lexapro
IViibryd neLexapro kufanele kugwenywe ngenkathi kuthathwa i-monoamine oxidase inhibitors (MAOIs), efana ne-selegiline ne-phenelzine. I-Viibryd noma i-Lexapro akufanele ithathwe zingakapheli izinsuku eziyi-14 zokuyeka i-MAOI noma kungahle kube nengozi eyengeziwe yesifo se-serotonin. IViibryd neLexapro kufanele futhi igwenywe noma ibhekwe nezinye izidakamizwa ze-serotonergic ezinjenge-anti-depressants, ezingakhuphula ubungozi be-serotonin syndrome.
Ukusetshenziswa kweViibryd noma iLexapro kufanele kubhekwe ngenkathi kuthatha umuthi wokulwa nokuvuvukala (i-NSAID) noma i-anticoagulant. Ukuthatha le mithi ndawonye kungandisa ingozi yokopha.
Ngenxa yokuthi iViibryd neLexapro ngokuyinhloko zakhiwe emzimbeni wesibindi, ukumuncwa kwazo kungathinteka yizidakamizwa eziguqula ama-enzyme athile wesibindi. Amanye ama-antifungal kanye nama-antibiotic angakhuphula amazinga e-Viibryd neLexapro egazini, okungakhuphula ubungozi bemiphumela emibi. Eminye imishanguzo efana nama-anticonvulsants anganciphisa amazinga egazi e-Viibryd neLexapro, anganciphisa ukusebenza kwawo jikelele.
ILexapro yaziwa ngokuthi ingadala ukuphazamiseka kwesigqi senhliziyo esibizwa ngokuthi yi-QT prolongation. Ukuthatha i-Lexapro ngemithi ethile elwa ne-antipsychotic efana ne-aripiprazole noma i-quetiapine kungakhuphula ingozi yokwandiswa kwe-QT.
| Izidakamizwa | Isigaba sezidakamizwa | Sbusisiwe | I-Lexapro |
| USelegilin I-Phenelzine I-Rasagiline | I-Monoamine oxidase inhibitors (MAOIs) | Yebo | Yebo |
| I-Paroxetine Sertraline I-Fluoxetine | I-serotonin reuptake inhibitors ekhethiwe (SSRIs) | Yebo | Yebo |
| I-Venlafaxine I-Desvenlafaxine I-Duloxetine | ISerotonin norepinephrine reuptake inhibitors (SNRIs) | Yebo | Yebo |
| Amitriptyline I-Clomipramine I-Nortriptyline | I-Tricyclic antidepressants (TCAs) | Yebo | Yebo |
| I-Bupropion | Aminoketone | Yebo | Yebo |
| I-Buspirone | I-Anxiolytic | Yebo | Yebo |
| I-Aspirin Ibuprofen I-Naproxen I-Diclofenac | Izidakamizwa ezingezona ukuvuvukala (ama-NSAID) | Yebo | Yebo |
| I-Warfarin | Ama-anticoagulants | Yebo | Yebo |
| I-Digoxin | I-glycoside yenhliziyo | Yebo | Yebo |
| I-Sumatriptan I-Rizatriptan I-Eletriptan | Ama-Triptans | Yebo | Yebo |
| Ketoconazole I-Itraconazole | Izikhunta | Yebo | Yebo |
| I-Ritonavir | Ama-Protease inhibitors | Yebo | Yebo |
| I-Clarithromycin | Imithi elwa namagciwane | Yebo | Yebo |
| I-Carbamazepine Phenytoin | Ama-anticonvulsants | Yebo | Yebo |
| I-Aripiprazole I-Clozapine I-Quetiapine | Ama-antipsychotic | Akunjalo | Yebo |
Thintana nochwepheshe wezokunakekelwa kwempilo mayelana nokunye ukuxhumana kwezidakamizwa okungenzeka.
Izexwayiso zeViibryd neLexapro
Ama-anti-depressants afana neViibryd noma iLexapro angakhuphula ubungozi bemicabango yokuzibulala, ikakhulukazi ezigulini zabantu abadala. Labo abathatha iViibryd noma iLexapro kufanele babhekwe ukwanda kokucindezeleka nemicabango yokuzibulala.
I-serotonin reuptake inhibitors ekhethiwe (i-SSRIs) inamandla okubangela i-serotonin syndrome, isimo esingaba simbi kakhulu esenzeka lapho kune-serotonin eningi kakhulu ebuchosheni. Ingozi iyanda lapho imishanguzo yokuthithibalisa ithathwa nezinye izidakamizwa ze-serotonergic. Izimpawu nezimpawu ze-serotonin syndrome zingafaka ukushaya kwenhliziyo okusheshayo, umfutho wegazi okhuphukile, ukujuluka, ukundindizela, nomkhuhlane.
Abanye abantu bangahlolwa umlando wesifo se-bipolar ngaphambi kokuqala ukwelashwa ngeViibryd noma ngeLexapro. Lezi zidambisi-mkhuba zinamandla okusebenzisa i-mania noma i-hypomania kwabanye abantu abane-bipolar disorder.
IViibryd neLexapro kufanele zicoshwe noma ziyekwe kancane kancane uma kudingeka. Ukuyekiswa okungazelelwe kwama-anti-depressants kungakhuphula ubungozi bezimpawu zokuhoxa.
Xhumana nomhlinzeki wezokunakekelwa kwempilo ukuthola ezinye izexwayiso nezinyathelo zokuqapha.
Imibuzo ebuzwa njalo ngeViibryd vs. Lexapro
Yini iViibryd?
IViibryd ngumuthi kadokotela osetshenziswa ukwelapha ukucindezeleka okukhulu (MDD). Yigama lomkhiqizo le-vilazodone. IViibryd isebenza njenge-serotonin reuptake inhibitor ekhethiwe (SSRI) kanye ne-5-HT1A receptor agonist. Imvamisa ithathwa njengethebhulethi ye-20 mg kanye ngosuku nokudla.
Kuyini iLexapro?
ILexapro ngumuthi wegama lomkhiqizo ogunyazwe yi-FDA ukwelapha ukucindezeleka okukhulu (MDD). Kubuye kuvunyelwe ukwelapha ukukhathazeka ngokweqile (GAD). Igama elijwayelekile likaLexapro yi-escitalopram. ILexapro yisidakamizwa se-SSRI esithathwa kanye nsuku zonke.
Ngabe i-Viibryd neLexapro ziyefana?
IViibryd neLexapro basebenza ngezindlela ezifanayo ukwelapha izimo zempilo yengqondo, kepha azifani. IViibryd isebenza njenge-SSRI ne-agonist eyisihlanu ye-5-HT1A kuyilapho iLexapro isebenza ngokuyinhloko njenge-SSRI. Yize uViibryd noLexapro bobabili bevunyelwe ukwelapha ukucindezeleka okukhulu, uLexapro naye uvunyelwe ukwelapha ukukhathazeka.
Ngabe iViibryd noma iLexapro ingcono?
I-anti-depressant engcono nguyena ophendula kahle kakhulu kuye. I-Viibryd neLexapro yomibili imishanguzo esebenza kahle kadokotela yokudangala. Uma kuqhathaniswa neLexapro, iViibryd ingadala imiphumela emibi yocansi.
Ngingayisebenzisa iViibryd noma iLexapro ngikhulelwe?
Ama-anti-depressants afana neViibryd noma iLexapro kungaphepha ukuthatha ngenkathi ukhulelwe. Kodwa-ke, abukho ubufakazi obanele bomtholampilo obukhombisa ukuthi iViibryd noma iLexapro iphephe ngokuphelele noma iyingozi ukuyithatha ngesikhathi sokukhulelwa. Le mithi kufanele ithathwe kuphela uma izinzuzo zidlula izingozi. Thintana nomhlinzeki wezokunakekelwa kwezempilo ukuthola iseluleko sezokwelapha ngokuthatha imishanguzo yokucindezela ukhulelwe.
Ngingayisebenzisa iViibryd noma iLexapro ngotshwala?
Ukuphuza ngokulinganisela kungenzeka kungadali monakalo uma ngabe ukwelashwa okungaguquki neViibryd noma iLexapro. Kodwa-ke, ukusetshenziswa kotshwala kungakhuphula ubungozi bemiphumela emibi, njengesizungu, ukozela nokudideka. Xhumana nomhlinzeki wezokunakekelwa kwezempilo ngokuphepha kwama-anti-depressants ngenkathi uphuza utshwala.
Ngabe i-Viibryd ilungele ukukhathazeka?
Isithako esisebenzayo eViibryd, vilazodone, sifundelwe ukwelashwa kokukhathazeka. Ngokuya ngokuhlolwa komtholampilo, i-vilazodone ingaba yi ukwelashwa okuphumelelayo yesifo sokukhathazeka esijwayelekile (GAD). Ucwaningo olwengeziwe luyadingeka nokho. Njengamanje, iViibryd ayivunyelwe i-FDA ukwelapha ukukhathazeka.
Ngisiphi isikhathi esihle sosuku sokuthatha iViibryd?
IViibryd kufanele ithathwe ngasikhathi sinye nsuku zonke. Ngokuya ngempendulo yomzimba wakho emithini, kungaba ngcono ukuthatha iViibryd ekuseni noma kusihlwa. Odokotela abaningi batusa ukuthatha iViibryd ekuseni ngesidlo sasekuseni.
Kwenzekani uma ngithatha iViibryd ngaphandle kokudla?
I-Viibryd ingahle ingasebenzi kahle uma ithathwa ngaphandle kokudla. Lokhu kungenxa yokuthi iViibryd imuncwa kangcono lapho iphathwa ngokudla. Uma kuqhathaniswa nokumuncwa kwayo nokudla, ukumuncwa kweViibryd ngaphandle kokudla kuncane cishe amashumi amahlanu% .
